Cardiac Screening with Electrocardiography, Stress Echocardiography, or Myocardial Perfusion Imaging

Similar documents
2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

Testing the Asymptomatic CAD Patient: When and Why?

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Efficiency

Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. Learn and Live SM. ACCF/AHA Pocket Guideline

Choosing the Appropriate Stress Test: Brett C. Stoll, MD, FACC February 24, 2018

MOHAMMED R. ESSOP DIVISION OF CARDIOLOGY CH-BARAGWANATH HOSPITAL

Stress Testing:Which Study is Indicated for My Patient?

Welcome! To submit questions during the presentation: or Text:

Reducing the Population Health Burden of Cardiovascular Disease

CCS Perioperative Guidelines When to order a BNP and What to do with a Positive Troponin

Blood Pressure LIMBO How Low To Go?

Dr. Suzanne Steinbaum Director, Women and Heart Disease Lenox Hill Hospital New York

The Failing Heart in Primary Care

Cardiovascular Disease

Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD

1. LV function and remodeling. 2. Contribution of myocardial ischemia due to CAD, and

Correlation of novel cardiac marker

Cardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology

Lipid Management 2013 Statin Benefit Groups

A Light in the Dark: Cardiac MRI and Risk Mitigation. J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED)

David A. Orsinelli, MD, FACC, FASE Professor, Internal Medicine The Ohio State University Division of Cardiovascular Medicine Columbus, Ohio

Optimal testing for coronary artery disease in symptomatic and asymptomatic patients

Screening for Asymptomatic Coronary Artery Disease: When, How, and Why?

Disclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Women and Heart Disease : Separating Fact from Fiction

CURRENT STATUS OF STRESS TESTING JOHN HAMATY D.O.

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

No relevant financial relationships

MEDICAL POLICY SUBJECT: CORONARY CALCIUM SCORING

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Physician Self-referral and Health Care Utilization. Rita F. Redberg, MD, MSc Professor of Medicine UCSF Medical Center

Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?

Diagnostic and Prognostic Value of Coronary Ca Score

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida

Case Question. Evaluation of Chest pain in the Office and Cardiac Stress Testing

I have no financial disclosures

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Current and Future Imaging Trends in Risk Stratification for CAD

Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD

Heart Disease in Women. Charlotte A. Lee, M.D., DBIM, FLMI

Evidence Synthesis Number 88

Cardiology Updates: Syncope and Stress Testing. Kathleen Morris, DO Cardiology Fellow St. Vincent Hospital

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

2017 Qualified Clinical Data Registry (QCDR) Performance Measures

The Journey from Evidence to Guidelines to Measures to Comparative Effectiveness

CVD risk assessment using risk scores in primary and secondary prevention

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Misperceptions still exist that cardiovascular disease is not a real problem for women.

Which Test When? Avoid the Stress of Stress Testing. Marc Newell, MD, FACC, FSCCT Minneapolis Heart Institute

Calculating Risk for Primary Prevention of Cardiovascular Disease (CVD)

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic

Cardiovascular Disease in Women -Vive La Difference? Dr Homeyra Douglas Consultant Cardiologist Aintree University Hospital

How would you manage Ms. Gold

Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.

Cardiac Stress Testing What Stress is Best?

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Efficiency High Priority

Cardiac CT Angiography

Women and Vascular Disease

ATP IV: Predicting Guideline Updates

Stress ECG is still Viable in Suleiman M Kharabsheh, MD, FACC Consultant Invasive Cardiologist KFHI KFSHRC-Riyadh

Statistical Fact Sheet Populations

MPS and Calcium Score in asymptomatic patient F. Mut, J. Vitola

Diabetes and the Heart

My Patient Needs a Stress Test

Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center

Overview. Health and economic burden of coronary artery disease (CAD) Pitfalls in care of patients suspected of having CAD

Preoperative Cardiac Risk Assessment: Approach & Guidelines

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Efficiency

When Should I Order a Stress Test or an Echocardiogram

Master class in preventive cardiology Focus on diabetes and cardiovascular disease Geneva April

Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines

Reducing Cardiovascular Risk in Adults. ACC Guidelines for Cholesterol Reduction: NCEP ATP CAOM Winter Seminar

Technical Meeting on: Current Role of Nuclear Cardiology in the Management of Cardiac Diseases Vienna, May 2008 Vienna International Centre

Use of Nuclear Cardiology in Myocardial Viability Assessment and Introduction to PET and PET/CT for Advanced Users

By: Diamond Fernandes BSc, ACSM CES, CSCS To learn more about the author, click below

PERIOPERATIVE EVALUATION AND ANESTHETIC MANAGEMENT OF PATIENTS WITH CARDIAC DISEASE FOR NON CARDIAC SURGERY

Placebo-Controlled Statin Trials

21st Annual Contemporary Therapeutic Issues in Cardiovascular Disease

The 2016 NASCI Keynote: Trends in Utilization of Cardiac Imaging: The Coronary CTA Conundrum. David C. Levin, M.D.

MYOCARDIALINFARCTION. By: Kendra Fischer

Clinical Controversies in Perioperative Medicine

ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW

UNITED STATES AIR FORCE AEROMEDICAL UPDATE AND REVIEW FOR AVIATORS WITH KNOWN CORONARY ARTERY DISEASE

Ischemic Heart Disease in Women

STRESSED ABOUT STRESS TESTS

Financial Disclosures. Coronary Artery Calcification. Objectives. Coronary Artery Calcium 6/6/2018. Heart Disease Statistics At-a-Glace 2017

DECLARATION OF CONFLICT OF INTEREST. None

2016 Qualified Clinical Data Registry (QCDR) Performance Measures

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

Management of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018

Young high risk patients the role of statins Dr. Mohamed Jeilan

Patient characteristics Intervention Comparison Length of followup

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Abbreviation List: 2017 by the American Heart Association, Inc. and the American College of Cardiology Foundation. 1

Women & Heart Disease Prevention

Risk Stratification for CAD for the Primary Care Provider

Placebo-Controlled Statin Trials Prevention Of CVD in Women"

Considering depression as a risk marker for incident coronary disease

Transcription:

Cardiac Screening with Electrocardiography, Stress Echocardiography, or Myocardial Perfusion Imaging A D V I C E F O R H I G H V A L U E C A R E F R O M T H E A M E R I C A N C O L L E G E O F P H Y S I C I A N S

Background Info. Cardiovascular disease causes 1 in 3 deaths in the U.S. or about 800,000 deaths per year Direct and indirect costs of coronary heart disease (CHD) in 2009 were estimated at $195 billion More than half of those who die suddenly of CHD have no antecedent symptoms

Screening Patients A good screening test aims to identify the condition in asymptomatic patients before it manifests clinically Often, inappropriate cardiac testing is done in low risk adults Low risk in this population defined as those with an estimated 10 year risk for CHD events of < 10% Want to use the most appropriate test for the patient s risk level

Evidence Based Recommendations for the Use of Cardiac Testing in Asymptomatic Adults The USPSTF advises - screen low risk adults with rest or exercise EKG The American College of Cardiology does not recommend cardiac screening in low risk adults In studies looking at low risk patients with resting EKG abnormalities, this did not move the patient from being in a low risk category to a high risk one little effect on clinical decisions

Low Risk Population The ACC and the AHA recommend against stress echo or MPI for cardiovascular risk assessment in low risk, asymptomatic adults One reason cardiac screening in this population is ineffective is that for many abnormalities found there is not proven, effective treatment (i.e. LVH) Controlling risk factors i.e. smoking, obesity, DM, HTN, etc. is indicated regardless of testing

Harms of Screening Pharmacologic agents to induce stress can cause myocardial ischemia, arrhythmia, hypotension, and bronchospasm Myocardial perfusion imaging results in radiation exposure from using radionuclide tracers False positives up to ¾ of asymptomatic men with exercise induced ST segment depression on EKG have no significant angiographic CAD Angiography is associated with a risk of ~1.7% for serious adverse events death, MI, stroke, and arrhythmia

Overuse of Cardiac Testing in Asymptomatic Adults Underestimation of harms associated with screening May overestimate the benefit of revascularization on the basis of trials that used outdated medical treatment regimens Possible thought that negative screening results reassures the patient Financial incentives i.e. greater increases in reimbursement for MPI s among cardiologists Patient satisfaction linked to financial incentives

How to Reduce Overuse of Cardiac Testing Many risk calculators available, Framingham risk calculator most validated Regardless of risk calculator, in patients in the low risk category, screening is not indicated and focus should be on treating modifiable risk factors i.e. smoking, diabetes, HTN, and HLD Recommendations in higher risk pts not as clear cut USPSTF found insufficient evidence to determine whether benefits of screening ECG outweigh harms

Risk Calculators (10 year risk of a CV event) Calculator Risk factors included Website Framingham risk score SCORE PROCAM Reynolds risk score Age, sex, total and HDL cholesterol, smoking, SBP, and anti-htnsive meds Age, sex, total and HDL cholesterol, smoking, and SBP Age, LDL and HDL, smoking status, SBP, family history, DM II, triglyceride levels Age, HgbA1C, smoking, SBP, total and HDL, hscrp, and parental history of MI < 60 http://cvdrisk.nhibi.nih.gov/calc ulator.asp www.heartscore.org/pages/welc ome.aspx www.myhealthywaist.org www.reynoldsriskscore.org

AHA and ACC Recommendations Recommend MPI as a potential option for CV risk assessment in high risk pts Evidence on effects of cardiac screening on clinical outcomes in higher risk pts is sparse and does not clearly show clinical benefit

Disease Audience Target Population Interventions Outcomes Benefits of Screening Harms of Screening High value care advice High Value Care Recommendations Cardiovascular disease Internists, family physicians, other clinicians Asymptomatic adults with low probability of cardiovascular disease EKG (resting or stress), stress echo, MPI Mortality (all cause and disease specific), cardiovascular events (MI, CHF, arrhythmia, SCD) Identification of undiagnosed CHD, identification of those at risk for cardiovascular events Stress test: sudden death, adverse effect of pharmacologic event, MPI: radiation, False Positives: anxiety, additional tests Clinicians should not screen for cardiac disease in asymptomatic, low risk adults with resting or stress EKG, stress echo, or stress MPI Clinical considerations Cardiovascular risk assessment in asymptomatic adults should start with a risk calculator, adhere to recommendations, treat modifiable risk factors and encourage exercise

Reference Annals of Internal Medicine Volume 162, No. 6 March 2015